Pharmacologic treatments for covid-19 patients
Convalescent plasma vs Standard care/Placebo
This comparison will not be updated. Last search date 14 Dec, 2022.
Studies included but not extracted/included in the analysis: Jalili E,Tanaffos, 2022; Denkinger C M, medrxiv, 2022 ; Thorlacius-Ussing L, Sci Rep, 2022; Villanueva C, medrxiv, 2022 ; Muller-Tidow C, Hemasphere, 2022
Outpatients
Forest plots
(last update: 2022-11-17)
Summary of findings
(last update: 2022-11-24)
Hospitalized patients
Forest plots
(last update: 2022-10-20)
Funnel plots
(last update: 2022-10-08)
Summary of findings
(last update: 2022-10-23)
To access all information :
You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.
Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=22
Back to your research
Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
---|---|---|---|---|---|---|---|---|
Treatment 1 | Treatment 2 | |||||||
NCT04385199 NCT04385199, Unpublished, 2022 Full text |
Not reported/unclear |
Convalescent plasma |
Standard care |
RCT | Patients with confirmed COVID-19 (severe-critical) admitted to a single center in the USA. | N=30 |
Some concerns Details |
|
NCT04429854 DAWN-plasma trial Devos T, Eur Respir J, 2021 Full text Commentary |
Public/non profit |
Convalescent plasma |
Standard care |
RCT | Patients with confirmed COVID-19 (mild-severe) admitted to 22 centers in Belgium | N=489 |
Some concerns Details |
|
NCT04539275 VACURES-1 NCT04539275, Unpublished, 2022 Full text |
Not reported/unclear |
Convalescent plasma |
Placebo |
RCT | Patients with confirmed COVID-19 (moderate) admitted to 24 centers in the USA. | N=75 |
Some concerns Details |
|
NCT04345991 CORIPLASM Lacombe K, Vox Sang, 2022 Full text |
Public/non profit |
Convalescent plasma |
Standard care |
RCT | Patients with confirmed COVID-19 (moderate) admitted to 14 centers in France. | N=120 |
Some concerns Details |
|
NCT04332835 Rojas M, BMC Infect Dis, 2022 Full text Commentary |
Mixed |
Convalescent plasma |
Standard care |
RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to three centers in Colombia | N=101 |
Some concerns Details |
|
NCT04362176 PassITON Self WH, Chest, 2022 Full text Commentary |
Public/non profit |
Convalescent plasma |
Placebo |
RCT | Patients with confirmed COVID-19 (mild-critical) admitted to 25 centers in USA. | N=974 |
Low Details |
|
NCT04803370 Bargay-Lleonart J, J Clin Med, 2022 Full text Commentary Commentary |
Public/non profit |
Convalescent plasma |
Standard care |
RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 3 hospitals in Spain. | N=55 |
Some concerns Details |
|
NCT04425915 COPLA-II trial Bajpai M, BMJ Open, 2022 Full text Commentary Commentary |
No specific funding |
Convalescent plasma |
Standard care |
RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 2 centers in India. | N=400 |
Some concerns Details |
|
NCT04405310 Fernandez-Sanchez V, Research Square, 2022 Full text Commentary Commentary |
Public/non profit |
Convalescent plasma |
Placebo |
RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to two centers in Mexico | N=43 |
Some concerns Details |
|
NCT04415086 COOP-COVID-19-MCTI Song ATW, Lancet Reg Health Am, 2022 Full text Commentary |
Public/non profit |
Convalescent plasma -High volume |
Convalescent plasma -Low volume |
RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to 7 centers in Brazil. | N=129 |
Some concerns Details |
|
NCT04621123 Alemany A, Lancet Respir Med, 2022 Full text Commentary Commentary |
Mixed |
Convalescent plasma |
Placebo |
RCT | Outpatients with confirmed COVID-19 (mild-moderate) treated at 4 centers in Spain. | N=376 |
Low Details |
|
NCT04516811 PROTECT-Patient van den Berg K, Sci Rep, 2022 Full text Commentary Commentary |
Public/non profit |
Convalescent plasma |
Placebo |
RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 4 centers in South Africa. | N=103 |
Low Details |
|
RBR-7f4mt9f De Santis GC, Emerg Infect Dis, 2022 Full text Commentary |
Public/non profit |
Convalescent plasma |
Standard care |
RCT | Patients with confirmed COVID-19 (severe-critical) admitted to 5 centers in Brazil | N=110 |
Some concerns Details |
|
ISRCTN85216856 Baldeon ME, Transfus Med, 2022 Full text Commentary |
Public/non profit |
Convalescent plasma |
Placebo |
RCT | Patients with suspected or confirmed COVID-19 (unclear severity) admitted to 3 centers in Ecuador. | N=158 |
Some concerns Details |
|
NCT04364737 CONTAIN COVID-19 Ortigoza MB, JAMA Intern Med, 2021 Full text Commentary Commentary |
Public/non profit |
Convalescent plasma |
Placebo |
RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 21 centers in the USA. | N=941 |
Some concerns Details |
|
NCT04600440 Holm K, BMC Res Notes, 2021 Full text Commentary |
Public/non profit |
Convalescent plasma |
Standard care |
RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to 2 centers in Sweden. | N=33 |
Some concerns Details |
|
NCT04589949, NCT04621123 COMPILE home Millat-Martinez P, Nat Commun, 2022 Full text Full text Full text Commentary Commentary Commentary |
Mixed |
Convalescent plasma |
Placebo |
RCT | Outpatients with confirmed COVID-19 (mild, symptomatic) treated by 14 centers in Spain and the Netherlands. | N=797 |
Low Details |
|
NCT04397757 PennCCP2 Bar KJ, J Clin Invest, 2021 Full text Full text Commentary |
Public/non profit |
Convalescent plasma |
Standard care |
RCT | Patients with confirmed COVID-19 (mild-severe) admitted to 2 centers in the USA. | N=80 |
Some concerns Details |
|
NCT04373460 Sullivan D, N Engl J Med, 2022 Full text Full text Commentary Commentary Commentary |
Mixed |
Convalescent plasma |
Placebo |
RCT | Outpatients (symptomatic, mild) with confirmed COVID-19 treated at 23 centers in the USA. | N=1225 |
Low Details |
|
NCT04716556 TSUNAMI Menichetti F, JAMA, 2021 Full text Commentary Commentary |
Public/non profit |
Convalescent plasma |
Standard care |
RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 27 centers in Italy. | N=487 |
Some concerns Details |
|
NCT04355767 SIREN-C3PO Korley F, N Engl J Med, 2021 Full text rid:crossref.org&rfr_dat=cr_pub%20%200pubmed Commentary |
Public/non profit |
Convalescent plasma |
Placebo |
RCT | Outpatients and patients with confirmed COVID-19 (symptomatic, mild to moderate) treated at or admitted to 48 centers in the USA. | N=511 |
Some concerns Details |
|
NCT04542941 Kirenga B, BMJ Open Respir Res, 2021 Full text Commentary Commentary |
Public/non profit |
Convalescent plasma |
Standard care |
RCT | Patients with confirmed COVID-19 (asymptomatic-severe) admitted to a single center in Uganda. | N=136 |
Some concerns Details |
|
NCT04547660 PLACOVID Sekine L, Eur Respir J, 2021 Full text Commentary |
Public/non profit |
Convalescent plasma |
Standard care |
RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to a single center in Brazil. | N=160 |
Some concerns Details |
|
NCT04348656 CONCOR-1 Begin P, Nat Med, 2021 Full text Full text Commentary Commentary Commentary |
Public/non profit |
Convalescent plasma |
Standard care |
RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 72 centers in Canada, USA and Brazil. | N=940 |
Some concerns Details |
|
NCT02735707 REMAP-CAP Estcourt L, JAMA, 2021 Full text Full text Commentary Commentary |
Mixed |
Convalescent plasma |
Standard care |
RCT | Patients with confirmed COVID-19 (severe-critical) admitted to 129 centers in Australia, Canada, UK, USA | N=2000 |
Low Details |